A venture capital firm with a major presence in Europe invests in life science companies through various funds. The firm targets seed, venture, and growth-stage investments in European companies but also considers North American and Asian opportunities. Initial investment size ranges from €500K – 10M, preferentially in the form of straight equity. The firm is capable of leading or co-investing in financing rounds; however, for U.S. deals, the firm prefers a local investor to lead unless it is a later-stage round (i.e., B, C, etc.) and the prior round was led by a U.S. investor. The firm has greater flexibility for European-based companies and typically leads these rounds. The firm is currently in investing mode, actively seeking opportunities, with the average investment ranging from €3–5M. 
 

The firm takes a true venture approach to investing and prioritizes breakthrough technologies with a strong IP position. Microbiome therapeutics and platforms are the primary interest, with willingness to invest as early as pre-clinical in this subsector. For other therapeutics, preferred phases of development are typically limited to pre-clinical investments into companies with a platform technology rather than those reliant on a single therapeutic asset. Medical technology and connected health companies are also evaluated, regardless of stage. 
 

The firm prefers to work with mature, experienced management teams but is open to all entrepreneurs. The firm will invest in pre-revenue as well as revenue-generating companies, with maximum revenues of €50M. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A global venture capital investor builds, incubates, and invests in biotech companies. The firm invests from an evergreen fund and prefers to invest at company formation or seed stage, with the latest stage being Series A. Typical investments range from $1-5M, but larger tranched investments may be made in therapeutic opportunities. With offices across multiple global hubs, the firm invests worldwide. The firm can act as either a lead or a co-investor. 

The firm’s investment strategy focuses on disruptive therapeutics platform technologies and novel therapeutic modalities. 

The firm prefers to back teams with a strong track record but is also open to first-time entrepreneurs. At company formation, the firm not only provides funding for initial proof-of-concept studies, but also supports the assembly of the founding team and other essential business development activities. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital firm founded in 2018 and based in the US actively invests in early-stage life science and healthcare companies with a focus on seed stage opportunities, investing up to $1M. The firm invests mostly in US, Europe, and Israel.  
 
The firm focuses on 2 areas: longevity and AI / future of healthcare. The firm is open to investing in therapeutics, medical devices, diagnostics, and digital health and will consider promising opportunities outside of these focus areas. 
 
The firm does not have specific management team requirements. The firm can lead or co-invest, and will typically seek board representation when leading investment rounds. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital investor primarily makes angel investments in seed-stage companies and works hands-on with portfolio companies to facilitate regulatory approval and commercialization. Typical initial check size is in the $500–750K range, with tranche investments possible beyond this amount. The firm is open to global opportunities. 

The firm focuses on therapeutics companies in the early stages of drug discovery and development. Current areas of interest include CNS and neurodegenerative diseases, oncology, and pulmonary diseases pursued with novel approaches. While the firm works primarily with pre-clinical opportunities, it may consider other indications from time to time. 

The firm’s long-term strategy is to help companies progress toward Phase II readiness for pre-clinical assets. With broad expertise in regulatory and toxicology matters, the firm takes a hands-on approach to supporting portfolio companies. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A global manufacturing company operates across a wide range of industries, including analytical, medical, and industrial equipment. In recent years, the firm has placed a strong focus on healthcare, particularly in clinical diagnostics and biomanufacturing. 

A few years ago, the firm established a corporate venture capital (CVC) division to seek strategic partnerships with companies that possess cutting-edge technologies aligned with its business areas.  

The firm has invested in companies across the U.S., Canada, and Asia and is actively looking to expand its portfolio. While the CVC primarily targets investments in Seed to Series A rounds, it may also consider Series B opportunities. Typical check sizes range from $1 million to $5 million USD, though larger investments are possible for particularly promising technologies. 

Within healthcare, the firm is seeking opportunities in clinical diagnostics, medical devices, and biomanufacturing. The firm is open to not only hardware but also consumables and software solutions. 

To attract investment from the CVC, having a lead investor is desirable. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital firm based in the US is actively investing in life science companies. The firm primarily invests in therapeutics companies in early and growth stage. Typical check sizes are in the $25-30M range over the company’s life cycle. The firm has a preference for companies based in Los Angeles and is passionate about fostering the local life science ecosystem, but the firm is also open to investing outside of LA given that the opportunity is a great fit. Outside of LA, the firm invests almost exclusively in the US. 
 
The firm invests in therapeutics in all disease areas and modalities, and is open to both single assets and platform technologies. The firm currently has over 20 companies in their portfolio, which can be reviewed here: https://westlakebio.com/portfolio for a better sense of where the firm has invested to date.  

The firm is open to pre-clinical to early clinical stage opportunities. The firm is open to investing in promising companies even in the idea/conception stage, and has done so in the past. 
 
The firm looks for compelling technologies and is open to investing in companies founded by first-time entrepreneurs. The firm prefers to be a lead investor, and has always led Series A investments and seeks board representation when leading. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A growth and venture investor based in the U.S. typically engages in pre-clinical and Seed stage life science startups. The firm invests in companies focused on significant unmet medical needs across contract services, manufacturing, equipment, and therapeutic companies. The firm supports entrepreneurs and early-stage companies by providing deep expertise, industry knowledge, and a network of proven experts to guide them through every stage of their life cycle. 

The firm is interested in pre-clinical therapeutics, digital health, medical devices, and diagnostic companies. The firm also invests in contract services, enabling technologies, and therapeutics across cell and gene therapies, oncology, antimicrobial resistance, neurosciences, and rare diseases. While indication-agnostic, the firm has particular expertise in oncology, neurosciences, rare disease, and antimicrobial resistance. 

The firm does not have strict company or management team requirements. The firm may take a board seat on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.